Voyager Therapeutics (VYGR) Competitors $3.28 -0.01 (-0.15%) As of 11:53 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock VYGR vs. AMLX, AVBP, IMTX, IMNM, NUVB, MGTX, GYRE, AUTL, PHAR, and DAWNShould you be buying Voyager Therapeutics stock or one of its competitors? The main competitors of Voyager Therapeutics include Amylyx Pharmaceuticals (AMLX), ArriVent BioPharma (AVBP), Immatics (IMTX), Immunome (IMNM), Nuvation Bio (NUVB), MeiraGTx (MGTX), Gyre Therapeutics (GYRE), Autolus Therapeutics (AUTL), Pharming Group (PHAR), and Day One Biopharmaceuticals (DAWN). These companies are all part of the "pharmaceutical products" industry. Voyager Therapeutics vs. Its Competitors Amylyx Pharmaceuticals ArriVent BioPharma Immatics Immunome Nuvation Bio MeiraGTx Gyre Therapeutics Autolus Therapeutics Pharming Group Day One Biopharmaceuticals Amylyx Pharmaceuticals (NASDAQ:AMLX) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends. Which has more risk & volatility, AMLX or VYGR? Amylyx Pharmaceuticals has a beta of -0.49, indicating that its stock price is 149% less volatile than the S&P 500. Comparatively, Voyager Therapeutics has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Is AMLX or VYGR more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -126.49%. Voyager Therapeutics' return on equity of -27.36% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -77.21% -63.84% Voyager Therapeutics -126.49%-27.36%-21.06% Does the media refer more to AMLX or VYGR? In the previous week, Amylyx Pharmaceuticals and Amylyx Pharmaceuticals both had 4 articles in the media. Amylyx Pharmaceuticals' average media sentiment score of 0.72 beat Voyager Therapeutics' score of -0.21 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Voyager Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do institutionals & insiders believe in AMLX or VYGR? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 11.7% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 6.4% of Voyager Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts prefer AMLX or VYGR? Amylyx Pharmaceuticals presently has a consensus target price of $11.75, indicating a potential upside of 42.94%. Voyager Therapeutics has a consensus target price of $13.39, indicating a potential upside of 308.85%. Given Voyager Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Voyager Therapeutics is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 2 Strong Buy rating(s) 3.00Voyager Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has better earnings & valuation, AMLX or VYGR? Voyager Therapeutics has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M8.39-$301.74M-$3.11-2.64Voyager Therapeutics$80M2.27-$65M-$1.46-2.24 SummaryAmylyx Pharmaceuticals and Voyager Therapeutics tied by winning 8 of the 16 factors compared between the two stocks. Get Voyager Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VYGR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VYGR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VYGR vs. The Competition Export to ExcelMetricVoyager TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$181.46M$3.07B$5.69B$9.49BDividend YieldN/A2.44%4.05%3.99%P/E Ratio-2.2521.0428.0020.03Price / Sales2.27251.99397.6083.98Price / CashN/A41.9636.1958.45Price / Book0.608.268.655.83Net Income-$65M-$55.19M$3.24B$258.39M7 Day Performance1.71%5.52%3.62%2.50%1 Month Performance9.17%18.20%11.16%12.85%1 Year Performance-63.20%7.33%35.16%21.38% Voyager Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VYGRVoyager Therapeutics3.8799 of 5 stars$3.28-0.2%$13.39+308.9%-63.0%$181.46M$80M-2.25100AMLXAmylyx Pharmaceuticals3.1821 of 5 stars$8.41+9.5%$11.75+39.7%+328.1%$749.68M-$1.27M-2.70200High Trading VolumeAVBPArriVent BioPharma2.2633 of 5 stars$21.87+1.1%$39.29+79.6%+7.1%$748.24MN/A-5.8040Positive NewsAnalyst ForecastAnalyst RevisionIMTXImmatics3.0324 of 5 stars$6.11+2.3%$14.67+140.0%-50.1%$742.67M$168.65M-35.94260News CoverageIMNMImmunome1.8566 of 5 stars$8.51-1.5%$23.33+174.2%-22.7%$740.46M$9.04M-2.6840NUVBNuvation Bio1.9489 of 5 stars$2.15-2.1%$7.17+232.7%-22.1%$732.92M$7.87M-0.9260MGTXMeiraGTx4.2639 of 5 stars$8.89+5.0%$24.00+170.0%+78.0%$714.40M$33.28M-3.83300News CoverageInsider TradeGYREGyre TherapeuticsN/A$7.61+1.6%N/A-50.3%$713.51M$105.76M380.6940AUTLAutolus Therapeutics2.6982 of 5 stars$2.65+7.3%$9.32+251.7%-37.5%$705.27M$10.12M-3.01330Positive NewsAnalyst ForecastPHARPharming Group2.4075 of 5 stars$10.35+3.5%$30.00+189.9%+15.2%$704.12M$320.71M-51.75280Positive NewsUpcoming EarningsDAWNDay One Biopharmaceuticals2.7714 of 5 stars$6.93+2.1%$29.00+318.5%-56.4%$702.44M$161.92M-9.7660Upcoming Earnings Related Companies and Tools Related Companies Amylyx Pharmaceuticals Alternatives ArriVent BioPharma Alternatives Immatics Alternatives Immunome Alternatives Nuvation Bio Alternatives MeiraGTx Alternatives Gyre Therapeutics Alternatives Autolus Therapeutics Alternatives Pharming Group Alternatives Day One Biopharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VYGR) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Voyager Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Voyager Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free VYGR Stock Alerts